FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C. 20549
---------------	------------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Landau Jeffrey B						2. Issuer Name and Ticker or Trading Symbol <u>CytomX Therapeutics, Inc.</u> [CTMX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify)					
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 12/20/2023								X Officer (give title Other (specify below) Chief Business Officer					
C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400					4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
ı	(Street) SOUTH SAN FRANCISCO CA 94080													X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	I - N	Ion-Deriva	ative	Secu	rities	Ac	quire	ed, Di	sposed o	f, or E	Beneficia	lly Own	ed				
Date			2. Transaction Date (Month/Day/	Year)	Execution Date,			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a 5)			Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(li		(Instr. 4)		
Common	Stock			12/20/20	23	.3			S ⁽¹⁾		4,077	D	\$1.3805	86,622(2)]	D		
Common Stock													4,5	00		I	Fidelity Traditional IRA		
Common Stock												3,180		I F		Schwab ROTH IRA			
		Tal	ble I	l - Derivati (e.g., pu							posed of, convertib			y Owne	d				
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Security or Exercise (Month/Day/Year) Execution Date, if any			4. Transa Code 8)	ransaction of ode (Instr. Derivative		rative rities ired r osed) r. 3, 4	Expiration Date (Month/Day/Year)			7. Titl Amou Secur Unde Deriv Secur 3 and	int of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownersi Form: Direct (I or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)		
					Code	v	(A)	(D)	Date Exe	e rcisable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs previously reported on December 19, 2023.
- 2. Includes 52,205 restricted stock units.

/s/ Lloyd Rowland, as Attorney-in-Fact for Jeffrey B 12/22/2023 Landau

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.